Social deprivation and foot disease outcomes in people with Diabetes Mellitus and Chronic Kidney Disease: A Systematic Reviews and Meta-Analysis Protocol
Open Access
- 6 June 2025
- journal article
- review article
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 8, 64
Abstract
Background Diabetes Mellitus (DM) and Chronic Kidney Disease (CKD) prevalence has increased and has raised multiple secondary concerns. Both conditions independently, and unanimously, contribute to the elevated morbidity and mortality rates in people with DM, increasing demands on healthcare systems. Patients presenting with CKD have greater levels of foot disease outcomes, including foot ulceration, amputation and subsequent mortality. These individuals are impacted with significant and complex clinical concerns with severe complications. However, the intricate interplay between CKD and diabetes-related foot disease outcomes in the context of social deprivation has not been investigated from an evidence synthesis perspective Aim We aim to identify if there is an association between social deprivation and foot disease outcomes in individuals with DM and CKD. Methods and analysis In accordance with the Preferred Reporting Items for Systematic Review and Meta-analyses, this protocol is reported in line with PRISMA-P guidelines. Three databases will be utilised to identify eligible studies reporting foot disease outcomes in people with DM and CKD. A MEDLINE search strategy was adapted to improve sensitivity and specificity for social deprivation-focused studies. Endnote and Covidence will manage records, with blinded screening and independent data extraction by three reviewers, with discrepancies resolved through discussion with a fourth reviewer. We will assess the risk of bias at both the study and outcome levels using established tools: the MOOSE Guidelines for meta-analysis in Observational studies and the JBI Manual for Evidence synthesis. Pooled odds ratios and standardised mean differences with 95% confidence intervals for nominal and continuous data will be calculated employing either a fixed-effects or random-effects model based on heterogeneity (I² < 50% for fixed-effects and I² > 50% for random-effects models). Sensitivity analyses will address missing data and heterogeneity, and GRADE will evaluate the quality of the evidence. PROSPERO registration number: CRD42024542991 Registration The systematic review protocol was published with the International Prospective Register of Systematic Review on the 12th of August, 2024 (registration number: CRD42024542991).Keywords
Funding Information
- HRB (SS-2024-045)
This publication has 28 references indexed in Scilit:
- Definitions and criteria for diabetes‐related foot disease (IWGDF 2023 update)Diabetes/Metabolism Research and Reviews, 2023
- KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney DiseaseKidney International, 2022
- Narrative Review of the Relationship Between CKD and Diabetic Foot UlcerKidney International Reports, 2021
- Clinical outcomes among patients with chronic kidney disease hospitalized with diabetic foot disorders: A nationwide retrospective studyEndocrinology, Diabetes & Metabolism, 2021
- MOOSE Reporting Guidelines for Meta-analyses of Observational StudiesJAMA Surgery, 2021
- Geospatial mapping and data linkage uncovers variability in outcomes of foot disease according to multiple deprivation: a population cohort study of people with diabetesDiabetologia, 2019
- Prospective comparison of search strategies for systematic reviews: an objective approach yielded higher sensitivity than a conceptual oneJournal of Clinical Epidemiology, 2016
- The association of chronic kidney disease and dialysis treatment with foot ulceration and major amputationJournal of Vascular Surgery, 2015
- Open bypass and endovascular procedures among diabetic foot ulcer cases in the United States from 2001 to 2010Journal of Vascular Surgery, 2014
- Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studyDiabetologia, 2010